Barclays Maintains Overweight on Alnylam Pharmaceuticals, Raises Price Target to $295
Portfolio Pulse from Benzinga Newsdesk
Barclays analyst Gena Wang maintains an Overweight rating on Alnylam Pharmaceuticals (NASDAQ:ALNY) and raises the price target from $291 to $295.
August 02, 2024 | 2:24 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Barclays analyst Gena Wang maintains an Overweight rating on Alnylam Pharmaceuticals and raises the price target from $291 to $295.
The maintained Overweight rating and increased price target from a reputable analyst at Barclays is likely to positively influence investor sentiment and drive short-term price appreciation for Alnylam Pharmaceuticals.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100